About Us

Eppin Pharma Inc. of Chapel Hill, North Carolina, is an emerging pharmaceutical company focused on developing a safe, non-hormonal male contraceptive taken orally. Our company was founded by Michael G. O’Rand, PhD, (Inventor, President, and CSO) at the University of North Carolina at Chapel Hill, Zahed Subhan, PhD, JD (CEO) at Western Carolina University, and Jeffrey A. Handler, PhD, DABT (COO), a board-certified toxicologist with broad experience in pharmaceutical and medical device research.

Management Team

 CEO: Zahed Subhan, Ph.D., MBA, JD, is a Professor of Marketing, Department of Marketing and Entrepreneurship, College of Business, Western Carolina University. Dr Subhan has had over 27 years of extensive experience in guiding pre-clinical and clinical development studies, and gaining regulatory approvals from FDA and EMEA agencies, as well as experience in executing major pharmaceutical product launches with multinational companies. Dr Subhan has also secured seed and venture capital funding for early stage biotechnology companies as Chief Executive Officer (>$25MM). As Chief Business Officer, Dr Subhan also contributed to the $100MM IPO (NASDAQ) of a Life Sciences (Genomics) Company. He has a Ph.D. in Pharmacology from the University of Leeds, UK, an MBA from the University of Bradford, UK and a JD Law from the University of London, UK.

President & CSO: Michael O’Rand, Ph.D., is a retired professor in the Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, School of Medicine.  Dr. O’Rand is a reproductive biologist and has more than 35 years of experience in studying mechanisms underlying human fertilization. Dr. O'Rand established the in vitro fertilization laboratory in UNC School of Medicine’s North Carolina Memorial Hospital and the first “test tube” baby in North Carolina. He has 5 issued or pending patents and more than 90 peer-reviewed publications. He has an A.B. from the University of California at Berkeley, an M.S. from Oregon State University, Corvallis, Oregon and a Ph.D. in Biology from Temple University, Philadelphia, PA.   


 COO: Jeffrey A. Handler, Ph.D., DABT, MBA, is a Board certified toxicologist with broad experience in many areas of pharmaceutical and medical device research and development in multiple therapeutic areas, including antibacterial, therapeutic and aesthetic dermatology, stroke, Alzheimer’s disease, diabetes, urinary incontinence and rheumatoid arthritis, obtained over more than 23 years in the pharmaceutical business. He has extensive leadership and management skills within pharmaceutical R&D ranging from drug discovery through development and support of commercialized products and a track record of successful collaboration with colleagues in both scientific and commercial business areas. He has a Ph.D. in Pharmacology (1987) from the University of North Carolina at Chapel Hill and an MBA (2005) from Villanova University, Villanova, PA.

Director of Laboratory Operations: Katherine G. Hamil, is a molecular biologist/biochemist with extensive experience in laboratory management and over 22 years of experience with molecular biology, biochemistry, and tissue culture techniques in the laboratory, with numerous publications in reproductive biology. She has an M.S. and B.S. in biochemistry and cellular and molecular biology from the University of North Carolina at Chapel Hill. NC.

Scientific Advisory Board

The Scientific Advisory Board (SAB) currently has three members.   Dr. O’Rand, inventor and co-founder of Eppin Pharma, serves as chair of the SAB.  The company is currently establishing relationships with additional accomplished scientists in reproductive biology, clinical research, and reproductive medicine to serve on Eppin Pharma’s Scientific Advisory Board.  The SAB will contribute expertise and guidance to Eppin Pharma’s business model and scientific strategy. 

Laneta Dorflinger, PhD

Distinguished Scientist and Director, Contraceptive Technology Innovation, FHI360, 359 Blackwell St., Durham, NC  27701 USA

Areas of expertise: Contraceptive technologies, HIV prevention research, Reproductive health, Hormonal contraception

 Gregory S. Kopf, PhD

Director, Research & Development, Global Health, Population & Nutrition, Contraceptive Technology Innovation, FHI360, 359 Blackwell St., Durham, NC  27701 USA

Areas of expertise: Reproductive health, Industry experience in women’s health (Wyeth), Contraceptive technology, reproductive (sperm and testis) biology

 John K. Amory MD, MPH

Professor of Medicine, Section Head, General Internal Medicine

University of Washington, Seattle WA

Areas of expertise: Board certified in internal medicine, Men’s reproductive health, Clinical evaluation of male contraceptives, Reproductive biology